Hospital General Universitario Gregorio Marañón-ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2024

  1. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  2. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  3. Risk of recurrence after discontinuing anticoagulation in patients with COVID-19- associated venous thromboembolism: a prospective multicentre cohort study

    eClinicalMedicine, Vol. 73

  4. The prognostic value of blood cellular indices in pulmonary embolism

    American Journal of Hematology, Vol. 99, Núm. 9, pp. 1704-1711

2023

  1. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

    Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 7

  2. Feasibility of a screening algorithm for chronic thromboembolic pulmonary hypertension: The OSIRIS study

    Thrombosis Research, Vol. 228, pp. 1-9

  3. Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations

    British Journal of Haematology, Vol. 201, Núm. 5, pp. 971-981

2022

  1. Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry

    Frontiers in Medicine, Vol. 9

2021

  1. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 8, pp. 1981-1989

  2. Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 2, pp. 408-416

  3. Validation of a prognostic score to identify hospitalized patients with covid-19 at increased risk for bleeding

    Viruses, Vol. 13, Núm. 11

2019

  1. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

    The Lancet Respiratory Medicine, Vol. 7, Núm. 11, pp. 951-963

  2. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years

    Scientific Reports, Vol. 9, Núm. 1

  3. Hospital volume and outcomes for acute pulmonary embolism: Multinational population based cohort study

    The BMJ, Vol. 366

  4. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry

    Orphanet Journal of Rare Diseases, Vol. 14, Núm. 1

2018

  1. Anticoagulant therapy for venous thromboembolism in patients with inflammatory bowel disease

    European Journal of Gastroenterology and Hepatology, Vol. 30, Núm. 5, pp. 526-530

  2. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism

    American Journal of Medicine, Vol. 131, Núm. 4, pp. 430-437

2017

  1. Predictors of active cancer thromboembolic outcomes: RIETE experience of the Khorana score in cancer-associated thrombosis

    Thrombosis and Haemostasis, Vol. 117, Núm. 6, pp. 1192-1198

2015

  1. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the lower limbs

    American Journal of Medicine, Vol. 128, Núm. 1, pp. 90.e9-90.e15